Breaking News Instant updates and real-time market news.

FOMX

Foamix

$3.76

-0.01 (-0.27%)

11:25
01/24/19
01/24
11:25
01/24/19
11:25

Foamix to host research and development day

Research and Development Day to be held in New York on January 24 at 12 pm. Webcast Link

  • 24

    Jan

FOMX Foamix
$3.76

-0.01 (-0.27%)

11/07/18
COWN
11/07/18
NO CHANGE
Target $30
COWN
Outperform
Foamix sale now more likely after Phase 3 trial successes, says Cowen
Cowen analyst Ken Cacciatore said that after Foamix Pharmaceuticals announced a successful Phase 3 program evaluating FMX103 in the treatment of moderate-to-severe papulopustular rosacea on the heels of the Phase 3 success in acne, he believes strategic interest will now likely accelerate. He notes that management indicated that they don't think they need additional capital to execute on their filing strategy or initial launch, which is "the type of commentary" he interprets as potentially signaling a willingness to entertain a potential business development deal or outright sale. Given the value of recent deals in the space, Cacciatore added that he believes Foamix shares are "meaningfully undervalued." The analyst keeps an Outperform rating and $30 price target on Foamix.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Foamix remains 'substantially undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Foamix Pharmaceuticals to $12 from $11 citing the positive top-line results from two pivotal Phase 3 clinical trials of FMX103 for the treatment of moderate-to-severe papulopustular rosacea. The analyst believes the high level of statistical significance underscores the degree of efficacy observed. He reiterates a Buy rating on Foamix and says the stock remains "substantially undervalued."
12/12/18
BOFA
12/12/18
INITIATION
Target $11
BOFA
Buy
Foamix initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Foamix with a Buy and $11 price target citing de-risked dermatology assets. Gerberry said Foamix offers two late-stage drugs with efficacy that are competitive to existing therapies but offer a topical alternative to widely used oral minocycline, with less safety baggage as a systemically absorbed drug. The analyst thinks FMX-101 and -103 will take market share and build recognition in the "experience-driven derm space."
12/12/18
12/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Foamix (FOMX) initiated with a Buy at BofA/Merrill. 2. Jazz Pharmaceuticals (JAZZ) initiated with an Outperform at Oppenheimer while GW Pharmaceuticals (GWPH) was initiated with a Perform. 3. Six Flags (SIX) initiated with a Buy at Berenberg. 4. iQIYI (IQ) initiated with a Hold at HSBC. 5. Intercept (ICPT), Viking Therapeutics (VKTX), and Galmed (GLMD) were initiated with a Buy at B. Riley FBR, while Madrigal Pharmaceuticals (MDGL) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

NIO

NIO Inc.

$8.01

0.395 (5.19%)

14:25
02/22/19
02/22
14:25
02/22/19
14:25
Options
NIO Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

14:25
02/22/19
02/22
14:25
02/22/19
14:25
General news
Action Economics Survey results: »

Action Economics Survey…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/22/19
02/22
14:17
02/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/22/19
02/22
14:16
02/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.27

-0.02 (-0.38%)

14:15
02/22/19
02/22
14:15
02/22/19
14:15
Hot Stocks
OCC issues cease and desist order against MUFG Bank over BSA violation »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

XOG

Extraction Oil & Gas

$4.64

0.83 (21.78%)

14:13
02/22/19
02/22
14:13
02/22/19
14:13
Recommendations
Extraction Oil & Gas analyst commentary  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$44.14

0.73 (1.68%)

14:10
02/22/19
02/22
14:10
02/22/19
14:10
Options
Size option spreads in iShares China Fund as the trade-hope rally continues »

Size option spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:09
02/22/19
02/22
14:09
02/22/19
14:09
Periodicals
China, U.S. remain far apart on intellectual property transfer, CNBC reports »

China has committed to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRN

Citi Trends

$20.69

0.28 (1.37%)

14:06
02/22/19
02/22
14:06
02/22/19
14:06
Initiation
Citi Trends initiated  »

Citi Trends initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 15

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

China agrees to buy $1.2…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$38.52

1.58 (4.28%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Recommendations
Cinemark analyst commentary  »

Cinemark Q4 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 11

    Mar

  • 02

    Apr

  • 02

    Apr

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

U.S., China remain far…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$52.93

0.58 (1.11%)

14:00
02/22/19
02/22
14:00
02/22/19
14:00
Options
Qualcomm calls lead puts 4:1 »

Qualcomm calls lead puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 12

    Mar

NVS

Novartis

$90.83

0.32 (0.35%)

, BIIB

Biogen

$324.70

3.71 (1.16%)

13:58
02/22/19
02/22
13:58
02/22/19
13:58
Periodicals
Novartis SMA therapy Zolgensma cost effective at up to $900,000, Reuters reports »

Zolgensma, an…

NVS

Novartis

$90.83

0.32 (0.35%)

BIIB

Biogen

$324.70

3.71 (1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 11

    Mar

  • 12

    Mar

  • 19

    Mar

  • 28

    May

BRQS

Borqs Technologies

$4.00

(0.00%)

13:48
02/22/19
02/22
13:48
02/22/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRQS

Borqs Technologies

$4.00

(0.00%)

13:43
02/22/19
02/22
13:43
02/22/19
13:43
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies Inc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$278.85

1.42 (0.51%)

, XLF

Financial Select Sector

$26.44

-0.07 (-0.26%)

13:41
02/22/19
02/22
13:41
02/22/19
13:41
Technical Analysis
On The Fly: ETF fund flow highlights »

For the week, ETF fund…

SPY

SPDR S&P 500 ETF Trust

$278.85

1.42 (0.51%)

XLF

Financial Select Sector

$26.44

-0.07 (-0.26%)

XLB

S&P Select Materials SPDR

$55.79

0.25 (0.45%)

BSV

Vanguard Short-Term Bond Index Fund

$78.99

0.11 (0.14%)

BIV

Vanguard Intermediate-Term Bond ETF

$82.51

0.285 (0.35%)

BLV

Vanguard Long-Term Bond ETF

$89.00

0.685 (0.78%)

IEF

iShares 7-10 Year Treasury Bond ETF

$104.65

0.35 (0.34%)

QQQ

Invesco QQQ Trust

$172.67

1.06 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$162.16

2.09 (1.31%)

13:40
02/22/19
02/22
13:40
02/22/19
13:40
Periodicals
NY Governor asks for probe of Facebook use of personal info, Bloomberg says »

New York Governor Andrew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

WEX

Wex

$176.23

5.88 (3.45%)

13:33
02/22/19
02/22
13:33
02/22/19
13:33
Earnings
Wex sees 2019 adjusted EPS $8.80-$9.20, consensus $8.94 »

Sees 2019 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.23

5.88 (3.45%)

13:32
02/22/19
02/22
13:32
02/22/19
13:32
Earnings
Wex reported preliminary 2018 adjusted EPS $8.18, consensus $8.18 »

Reported preliminary 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.24

5.89 (3.46%)

13:29
02/22/19
02/22
13:29
02/22/19
13:29
Hot Stocks
Wex delays earnings on up to $70M Brazilian subsidiary discrepancy »

Wex announced earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

WEX

Wex

$176.53

6.18 (3.63%)

13:26
02/22/19
02/22
13:26
02/22/19
13:26
Periodicals
Wex CEO tells Bloomberg business 'incredibly healthy' despite Brazil issue »

WEX's overall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
Xerox rating change  »

Xerox downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.55

0.75 (0.84%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Downgrade
United Continental rating change  »

United Continental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

13:20
02/22/19
02/22
13:20
02/22/19
13:20
Periodicals
U.S, China disusing late March summit between Xi and Trump, CNBC reports »

U.S. and China are…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.89

1.46 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.